Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
Stopped early · Phase 2
Conditions studied: Squamous Cell Carcinoma Of The Head And Neck
In brief
This is a single-arm, non-masked, open-label, Phase II study of cetuximab + dasatinib in recurrent Squamous Cell Carcinoma of The Head and Neck (SCCHN) that has recurred after cetuximab-containing therapy (please see attached schema). The primary endpoint 12-week PFS.
Key facts
- Study ID
- NCT01488318
- Run by
- Julie E. Bauman, MD, MPH
- People needed
- 21
- Starts
- 2011-09-01
- Expected to finish
- 2016-08-01
- Last updated by the study team
- 2018-01-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.